Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and maintain a list of applications available to provide content. The first application can send a request to a second application identified in the list, the request including a key that indicates the first application is authorized to request the second application to search for content. The first application can obtain a search result from the second application based on the request and present the search result in a user interface in the first application.

Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and maintain a list of applications available to provide content. The first application can send a request to a second application identified in the list, the request including a key that indicates the first application is authorized to request the second application to search for content. The first application can obtain a search result from the second application based on the request and present the search result in a user interface in the first application.

Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and maintain a list of applications available to provide content. The first application can send a request to a second application identified in the list, the request including a key that indicates the first application is authorized to request the second application to search for content. The first application can obtain a search result from the second application based on the request and present the search result in a user interface in the first application.

Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and maintain a list of applications available to provide content. The first application can send a request to a second application identified in the list, the request including a key that indicates the first application is authorized to request the second application to search for content. The first application can obtain a search result from the second application based on the request and present the search result in a user interface in the first application.

Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and provide a request to a second application to search for content associated with the second application that corresponds to the search query. The request can include a key that indicates to the second application that the first application is authorized to request the second application to search for the content. The first application can obtain a search result from the second application based on the request an present the search result in a user interface for the first application.

Abstract: Disclosed are various examples of providing a secured application launcher for initiating execution of access-restricted applications. A computer disables a default launch activity alias for a user application, wherein the default launch activity alias comprises a first reference to an application programming interface (API) to initiate execution of the user application. The computer then queries the user application for a presence of a container activity alias provided by the user application, wherein the container activity alias comprises a second reference to the API to initiate execution of the user application. The computer then displays an application icon representing the user application based at least in part on the presence of the container activity alias. The computer then calls the container activity alias for the user application based at least in part on a manipulation of the application icon.

Abstract: Disclosed are examples of searching for content associated with multiple applications. In various examples, a first application can obtain a search query and provide a request to a second application to search for content associated with the second application that corresponds to the search query. The request can include a key that indicates to the second application that the first application is authorized to request the second application to search for the content. The first application can obtain a search result from the second application based on the request an present the search result in a user interface for the first application.

Abstract: Disclosed are various examples of providing a secured application launcher for initiating execution of access-restricted applications. A computer disables a default launch activity alias for a user application, wherein the default launch activity alias comprises a first reference to an application programming interface (API) to initiate execution of the user application. The computer then queries the user application for a presence of a container activity alias provided by the user application, wherein the container activity alias comprises a second reference to the API to initiate execution of the user application. The computer then displays an application icon representing the user application based at least in part on the presence of the container activity alias. The computer then calls the container activity alias for the user application based at least in part on a manipulation of the application icon.

Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.

Abstract: Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA).

Abstract: This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages.

Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.

Abstract: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.

Abstract: An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures thereof.

Abstract: Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA).

Abstract: Disclosed are methods of introducing a suspension or solution of a medicament, preferably mometasone furoate anhydrous, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of introducing mometasone furoate anhydrous, a surfactant and a chlorofluorocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, circulating said suspension or solution from the vessel through a line which includes a filling head, bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container, introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container, withdrawing said filling head from said metered dose inhaler container, and sealing said metered dose inhaler container, as well as the products produced thereby having an improved particle size

Abstract: Disclosed are metered dose inhalers having a metering valve to deliver a dose containing an aerosol suspension formulation, said aerosol suspension formulation comprising: an effective amount of Mometasone Furoate, Formoterol or a combination thereof; a suspension medium selected from the group consisting of 1,1,1,2,3,3,3,-heptafluoropropane, 1,1,1,2-tetrafluoroethane; and a solvent that is ethanol; wherein said formulation contains less than about 500 ?g of non-volatile residue as measured by ultraviolet spectroscopy.

Abstract: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.

Abstract: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent including the solution is a pleconaril-dissolving hydrofluorocarbon.

Abstract: An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures thereof.